Abstract
The genomic profiling of circulating tumor cells (CTCs) in the bloodstream should provide clinically relevant information on therapeutic efficacy and help predict cancer survival. However, the molecular characterization of CTCs has so far proven extremely difficult. A variety of technologies have been developed for CTC isolation, but so far the impact on the genomic assessment of CTCs has not been fully evaluated. To fill this gap, here we contrasted the genomic profiles of CTC pools recovered from blood samples obtained from four metastatic colorectal cancer (mCRC) patients using three different enrichment strategies (CellSearch, Parsortix, and FACS). Our results suggest clear differences in the mutational burden of CTC pools depending on the enrichment method used, with all evaluated methods returning a somewhat limited representation of the mutational spectrum of individual tumors, potentially due to allelic dropout during whole-genome amplification. Nevertheless, the CTC pools from Parsortix, and in part, CellSearch, showed diversity estimates, mutational signatures and drug-suitability scores remarkably close to the ones found in matching primary tumor samples. In contrast, FACS CTC pools were substantially enriched in apparent sequencing artifacts, which led to much higher estimates of genomic diversity. Although CTC genomics still faces technical challenges, our results suggest that CTC-derived metrics can reflect the diversity scores seen in primary tumor lesions thus highlighting the utility of CTCs to assess the heterogeneity status of individual tumors, and to help clinicians prioritize drugs in mCRC.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by an AXA Research Fund postdoctoral grant (awarded to J.M.A), and by the Spanish Ministry of Science and Innovation - MICINN (PID2019-106247GB-I00 awarded to D.P.). J.M.A. is currently supported by the AECC (INVES20007FERN). D.P. receives further support from Xunta de Galicia. M.V. is supported by an H2020/ Marie Skłodowska-Curie Actions EU research framework programme grant (Project H2020 MSCA-ITN-2017-766030). L.T. received support from a Ph.D. fellowship from Xunta de Galicia (ED481A-2018/303). J.C. received grants from Spain's Carlos III Health Care Institute (Co-funded by European Regional Development Fund/European Social Fund "A way to make Europe"/"Investing in your future"), No. PI17/00837 and PI21/01771. J.C. is additionally funded by the Agencia Gallega de Innovacion (N607B-2020/02). R.P. received support from Roche-Chus Joint Unit (IN853B 2018/03) funded by Axencia Galega de Innovacion (GAIN), Conselleria de Economia, Emprego e Industria.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All specimens used in this study were obtained and collected after written informed consent from all subjects using a protocol approved by the Clinical Ethic Committee of Pontevedra-Vigo-Ourense (2018/301 approved 19/06/2018).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Competing interests: The authors declare no competing interests.
Data Availability
All raw whole exome sequencing data used in this study will be available at the Sequence Read Archive database.